Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending-dose intratympanic AC102 study in healthy volunteers
NL-OMON55334Phase 1Active, not recruiting
- Sponsor
- AudioCure Pharma GmbH
- Start
- Jul 2020
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1 trial of AC102 in acute sensorineural hearing loss, Hypoacusis and tinnitus (2 arms), sponsored by AudioCure Pharma GmbH. Primary endpoints: Treatment-emergent (serious) adverse events, Adverse events of special interest and 10 more. Started Jul 2020; status: active, not recruiting.
02
Drugs
AC102
03
Conditions
acute sensorineural hearing lossHypoacusistinnitus
Beyond the preview
Go deeper on NL-OMON55334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55334.